Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Nimbus

- PMLiVE

Merck wins speedy FDA review for 15-valent pneumococcal vaccine

Pfizer's rival 20-valent candidate was granted priority review in December 2020

- PMLiVE

Keytruda claims first blood cancer OK from FDA

Merck & Co wins US approval for its haematological cancer treatment

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

- PMLiVE

Medical device M&A hit ‘all-time high’ in 2014

Deals last year were led by Medtronic’s acquisition of Covidien

- PMLiVE

UPDATE: Merck to acquire Cubist for $8.4bn

Will expand company's presence in antibiotics

- PMLiVE

Merck files once-weekly DPP-4 inhibitor in first market

Picks Japan to submit omarigliptin

- PMLiVE

Merck buys rights to NewLink’s Ebola vaccine

Drug is set to enter large phase III study in early 2015

- PMLiVE

Merck & Co’s cancer drug Keytruda gaining traction in US

Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval

- PMLiVE

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links